The Latest Breaking News from Roivant

Roivant stock is nearing a breakout Tuesday after the company announced positive results in an eye-disease study and a $1.5 billion buyback.

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

He bills himself as an iconoclast ready to shake up the Republican Party after making millions trying to do the same in the biotech industry.

Biotech stock Roivant — founded by presidential candidate Vivek Ramaswamy — reported steep losses and lighter sales.

Roche is in discussions to buy a stomach-disease treatment from Roivant for around $7 billion. The report sent ROIV stock surging Friday.

Roivant said Thursday more than a third of ulcerative colitis patients entered remission in its study. ROIV stock hit a buy point on the news.

Yale's Sonnenfeld and Tian retrace presidential hopeful Vivek Ramaswamy's business record.

Merck is acquiring Prometheus Bio in a well-timed $10.8 billion deal ahead of Keytruda's patent loss. The news sent RXDX stock flying Monday.

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant.  Pfizer holds a 25%…